01 / PSC Market Profile
PSC AN13 Health R&D Services; Health Care Services; Experimental Development Federal Contracts
Product and Service Code AN13
Federal contract activity classified under Health R&D Services; Health Care Services; Experimental Development across FY 2019–FY 2025. Net obligations include both new obligations and subsequent deobligations.
02 / Market Size
How large is the PSC AN13 federal market?
03 / Spending Trend
PSC AN13 contract spending by fiscal year
Annual obligations, activity, and participation across the same FY 2019–FY 2025 profile window.
Latest closed fiscal year$50.87M
FY 2025| Fiscal year | Obligations | Actions | Vendors | Customers | Change |
|---|---|---|---|---|---|
| FY 2019 | $487.26M | 297 | 135 | 9 | — |
| FY 2020 | $2.31B | 370 | 148 | 6 | +374.1% |
| FY 2021 | $142.74M | 387 | 172 | 7 | −93.8% |
| FY 2022 | $774.33M | 494 | 181 | 7 | +442.5% |
| FY 2023 | $1.37B | 445 | 199 | 8 | +77.1% |
| FY 2024 | $513.03M | 477 | 210 | 8 | −62.6% |
| FY 2025 | $50.87M | 441 | 187 | 6 | −90.1% |
04 / Top Federal Customers
Which federal agencies buy most in this industry?
Ranked by net obligations during FY 2019–FY 2025.
| Federal customer | Code | Obligations | Actions | Vendors | Market share |
|---|---|---|---|---|---|
| OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | 7505 | $5.11B | 1,995 | 238 | 90.4% |
| NATIONAL INSTITUTES OF HEALTH | 7529 | $347.39M | 417 | 79 | 6.1% |
| DEPT OF THE ARMY | 2100 | $185.99M | 262 | 64 | 3.3% |
| DEFENSE HEALTH AGENCY (DHA) | 97DH | $84.77M | 110 | 35 | 1.5% |
| VETERANS AFFAIRS, DEPARTMENT OF | 3600 | $18.35M | 87 | 28 | 0.3% |
| CENTERS FOR DISEASE CONTROL AND PREVENTION | 7523 | $8.49M | 8 | 5 | 0.2% |
| FOOD AND DRUG ADMINISTRATION | 7524 | $1.56M | 15 | 6 | 0.0% |
| DEPT OF THE NAVY | 1700 | $876.3K | 6 | 1 | 0.0% |
| OFFICE OF PROCUREMENT OPERATIONS | 7001 | $30.0K | 1 | 1 | 0.0% |
| ENERGY, DEPARTMENT OF | 8900 | -$3.3K | 3 | 1 | 0.0% |
05 / Contracting Offices
Which contracting offices buy in PSC AN13?
Ranked by net obligations during FY 2019–FY 2025.
| Office | Code | Agency | Obligations | Actions | Vendors | Market share |
|---|---|---|---|---|---|---|
| BARDA - ASPR / DAAPPO / BARDA DCMA | 75A501 | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | $5.11B | 1,995 | 238 | 90.4% |
| NIH NCI | 75N910 | NATIONAL INSTITUTES OF HEALTH | $297.60M | 233 | 57 | 5.3% |
| W4PZ USA MED RSCH ACQUIS ACT | W81XWH | DEPT OF THE ARMY | $136.65M | 234 | 51 | 2.4% |
| ARMY MED RES ACQ ACTIVITY | HT9425 | DEFENSE HEALTH AGENCY (DHA) | $84.77M | 110 | 35 | 1.5% |
| W6QK ACC-APG NATICK | W911QY | DEPT OF THE ARMY | $47.90M | 21 | 8 | 0.8% |
| NATIONAL INSTITUTES OF HEALTH NIAID | 75N930 | NATIONAL INSTITUTES OF HEALTH | $25.34M | 123 | 18 | 0.4% |
| SAC FREDERICK (36C10X) | 36C10X | VETERANS AFFAIRS, DEPARTMENT OF | $14.49M | 25 | 4 | 0.3% |
| ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H) | 75N992 | NATIONAL INSTITUTES OF HEALTH | $10.48M | 33 | 14 | 0.2% |
| CDC OFFICE OF ACQUISITION SERVICES | 75D301 | CENTERS FOR DISEASE CONTROL AND PREVENTION | $8.49M | 8 | 5 | 0.2% |
| NATIONAL INSTITUTES OF HEALTH NIDA | 75N950 | NATIONAL INSTITUTES OF HEALTH | $8.04M | 12 | 3 | 0.1% |
06 / Top Vendors
Which contractors lead the PSC AN13 market?
| Vendor | Obligations | Actions | Customers | Market share | Latest activity |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | $807.34M | 27 | 1 | 14.3% | Aug 8, 2025 |
| AMGEN USA INC. | $714.82M | 13 | 1 | 12.7% | Jul 15, 2025 |
| SIGA TECHNOLOGIES, INC. | $575.13M | 25 | 1 | 10.2% | Jun 3, 2025 |
| EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC | $470.89M | 16 | 1 | 8.3% | Jul 5, 2024 |
| MAPP BIOPHARMACEUTICAL, INC. | $154.07M | 57 | 3 | 2.7% | Aug 25, 2025 |
| EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | $142.69M | 36 | 2 | 2.5% | Jul 8, 2025 |
| VENATORX PHARMACEUTICALS, INC. | $127.51M | 36 | 1 | 2.3% | Sep 3, 2025 |
| ASTRAZENECA PHARMACEUTICALS LP | $125.65M | 9 | 1 | 2.2% | Nov 27, 2020 |
| BATTELLE MEMORIAL INSTITUTE | $110.80M | 287 | 1 | 2.0% | Sep 30, 2025 |
| MODEX THERAPEUTICS LLC | $110.05M | 5 | 1 | 1.9% | Mar 18, 2025 |
07 / Industry Mix
What industries are purchased under PSC AN13?
| NAICS | Description | Obligations | Actions | Vendors | Share |
|---|---|---|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | $2.93B | 900 | 158 | 51.8% |
| 541711 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY | $1.32B | 730 | 74 | 23.4% |
| 541715 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) | $689.58M | 691 | 150 | 12.2% |
| 236210 | INDUSTRIAL BUILDING CONSTRUCTION | $470.89M | 11 | 1 | 8.3% |
| 325412 | PHARMACEUTICAL PREPARATION MANUFACTURING | $131.91M | 41 | 7 | 2.3% |
| 541713 | RESEARCH AND DEVELOPMENT IN NANOTECHNOLOGY | $91.84M | 137 | 9 | 1.6% |
| 541611 | ADMINISTRATIVE MANAGEMENT AND GENERAL MANAGEMENT CONSULTING SERVICES | $43.60M | 19 | 2 | 0.8% |
| 424210 | DRUGS AND DRUGGISTS' SUNDRIES MERCHANT WHOLESALERS | $40.90M | 12 | 1 | 0.7% |
| 325413 | IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING | $39.82M | 50 | 12 | 0.7% |
| 541712 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) | $37.58M | 150 | 31 | 0.7% |
08 / Buying Pattern
How does the government buy in PSC AN13?
| Common action type | Obligations | Actions |
|---|---|---|
| DEFINITIVE CONTRACT | $4.58B | 2,065 |
| DELIVERY ORDER | $900.27M | 706 |
| PURCHASE ORDER | $172.71M | 140 |
09 / Recent Contract Awards
What was awarded most recently in PSC AN13?
10 / Market Interpretation
How should contractors evaluate this market?
Start with the spending direction
Compare annual obligations with actions and vendor participation. Growth driven by only a few large actions represents a different opportunity from broad, recurring demand.
Follow the actual buyers
Move from federal customers to contracting offices. Offices reveal where acquisition responsibility and recurring purchasing activity are concentrated.
Measure accessible demand
Use competition, small-business participation, incumbent vendors, and PSC mix before treating the full $5.65B market as addressable.